Research programme: osteoarthritis therapeutic - Transition TherapeuticsAlternative Names: TT-601
Latest Information Update: 23 Apr 2014
At a glance
- Originator Eli Lilly
- Class Small molecules
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 07 Apr 2014 Discontinued - Preclinical for Osteoarthritis in USA (unspecified route)
- 23 Jul 2013 Preclinical trials in Osteoarthritis in USA (unspecified route)